expression analysis, careful isolation of the proper cell subsets, and controlled in vitro stimulations with respect to dose and timing.
eQTLs may act in cis (regulatory variants located near the gene under regulation), or in trans (regulation by variants at great distance, including on different chromosomes). There are many examples of cis regulation, but trans regulation has been more diffi cult to sort out due to its complexity and the large number of potential variants to investigate. It is therefore gratifying that both studies show an integrated network of cis and trans regulation. Fairfax et al. identify, within the Toll-like receptor (TLR) pathway (which responds to bacterial LPS), the transcription factor interferon regulatory factor 2 (IRF2) as an eQTL in monocytes. Lee et al. demonstrate trans-eQTLs of IRF7 in dendritic cells under several conditions. Adding to this complexity, it is apparent that trans-eQTLs can also be time dependent, mediated indirectly through intervening signaling pathways. For example, interferon B1 (IFNB1) is among the cis-eQTLs in monocytes that is induced by LPS at 2 hours after exposure. However, at 24 hours after exposure, this cis-eQTL is no longer observed, but multiple trans-eQTLs appear in pathways downstream of IFNB1. Although Lee et al. restricted their full analyses of LPS-triggered responses to an early time point (5 hours after exposure), it is clear from their exploratory time-course data that similarly connected time-dependent eQTL responses are likely to exist in dendritic cells. One example of an additional mechanistic twist involves a coding-region eQTL in the gene encoding cytochrome P450 1B1 that leads to shortened protein half-life and consequent compensatory feedback on transcription of its own mRNA. Clearly, the experimental details are critical for eQTL discovery and mechanistic understanding.
Such information can be applied to understanding GWAS data. For example, the haplotype bearing the IRF7 trans-eQTL contains a single-nucleotide polymorphism that is associated with systemic lupus and is also an eQTL for induction of a robust interferon response to viral exposure (see the fi gure), a fi nding consistent with abnormal regulation of interferon in this disease ( 3) . Similarly, Fairfax et al. show that an interferondependent eQTL in the gene encoding caspase recruitment domain-containing protein 9 (CARD9), a protein associated with the infl ammatory bowel disorder Crohn's disease ( 4) , is actually a secondary independent disease-associated variant in the CARD9 locus. Indeed, the studies of Fairfax et al. and Lee et al. reveal a great deal of overlap between eQLT loci and a variety of immune-related disorders. Furthermore, Lee et al. show that many eQTL loci have multiple variants with distinct effects, emphasizing the complexity of interpreting associations identifi ed by GWAS, even at a single locus.
An intriguing observation by Fairfax et al. is that interferon acts through the MHC to induce many trans-eQTL effects in isolated monocytes. The MHC is one of the most gene-dense and highly polymorphic regions in the genome, so it can be diffi cult to pinpoint exactly which genetic variants are responsible for these trans-eQTL effects. The MHC is the predominant genetic locus controlling adaptive immunity and many autoimmune diseases, primarily through interactions with T cell receptors. For these eQTL effects on monocytes, however, T cells are not present in the system. Nevertheless, eQTL effects are correlated with the ciseQTL effects on class II MHC expression, suggesting that the class II molecules themselves may be mechanistically involved. This is consistent with studies showing intracellular signaling by MHC class molecules ( 5), as well as their ability to modify signaling, through TLR pathways ( 6) .
eQTLs for gene expression that are cell type-and context-specifi c will be refl ective of quantitative immune traits at the system and organismal levels ( 7, 8) , which in turn constitute phenotypes that are likely to determine disease susceptibility ( 9) . Elucidating these relationships is a major challenge, and will require extensive collaboration among clinical and basic investigators, as well as scientists with advanced computational expertise. M olecular biology and evolutionary biology have been separate disciplines and scientific cultures: The former is mechanistic and focused on molecules; the latter is theoretical and focused on populations. However, these domains are beginning to converge in laboratories addressing molecular mechanisms that explain how evolutionary processes work, and bring these processes to bear on medical problems such as cancer and infectious disease. Each discipline can be viewed as a missing link in the other's description of biology, and in medicine.
Traditional evolutionary biology began in the 1930s with the "modern synthesis," which fused Darwin's theses on phenotypic variation and selection with Mendel's concepts of genetic inheritance to explain the source of biological diversity. This synthesis predated knowledge that genes were made of DNA and of the structure of DNA and how it replicates. Thus, molecular mechanisms could not be integrated into concepts about how phenotypic variation is generated. Instead, assumptions had to be made about the origins of the variation that drives evolution. Among the cornerstone assumptions were that mutations are the sole drivers of evolution; mutations occur randomly, constantly, and gradually; and the transmission of genetic information is vertical from parent to offspring, rather than horizontal (infectious) between individuals and species (as is now apparent throughout the tree www.sciencemag.org SCIENCE VOL 343 7 MARCH 2014 PERSPECTIVES of life). But discoveries of molecular mechanisms are modifying these assumptions.
In at least two ways, heritable variation can be generated by proteins, not DNA ( 1). Spontaneously self-aggregating alternative conformations of some proteins-prionscan fl ip into their aggregated state and change a cell's phenotype in an environmentally responsive manner with no change to DNA. The change is transmissible vertically, parent to offspring cell, as well as horizontally, to other cells in which the proteins come in contact. Another mechanism involves chaperones such as heat shock protein 90 (Hsp90), proteins that massage subideal (mutant) proteins into functional conformations but abandon their regular client proteins during heat and other stresses that destabilize proteins. This causes a stress-inducible release of phenotypic diversity, which may drive evolution (with phenotypes ultimately stabilized by subsequent genetic changes). Both of these molecular mechanisms of protein-based inheritance are major departures from the modern synthesis views of solely mutationdirected variation, solely genetic inheritance, and independence of the generation of variation from environmental conditions.
Similarly, transient errors in mRNA synthesis can also cause heritable non-DNAbased phenotypic change. This is observed when low-abundance transcriptional regulators are affected by transcription errors. This disruption can cause a cell to alter its gene expression, resulting in a phenotype that may be heritable ( 2) .
Even the assumption that mutations are random, constant, and gradual has been revised on the basis of molecular mechanisms of mutagenesis. For example, in bacteria, responses to environmental stress can activate mutagenesis mechanisms that increase mutation rate, which can potentially increase the ability of a cell to evolve, specifically when it is poorly adapted to its environment (when stressed). Most of a 93-gene network that promotes mutagenesis in Escherichia coli is devoted to sensing stress and activating stress responses that direct the bacterium to mutate when stressed ( 3) . Stress responses also up-regulate mutagenesis in yeast ( 4) and human cancer cells ( 5) and underlie mutations induced by antibiotics that cause resistance to those very drugs, and others ( 6) .
Mutations are also nonrandom in genomic space-for example, forming hot spots at DNA double-strand breaks, as demonstrated in bacteria ( 7) and suggested by local clusters of mutations in cancer genomes ( 8, 9) . In cancer, the mutations are generated by cytidine deaminases that target single-stranded DNA regions ( 10), presumably at DNA breaks. Additionally, the structure of the human genome with regard to repetitive DNA ( 11) and three-dimensional structure ( 12, 13) predisposes certain regions to copy number variation because of recombination between repeats ( 11) or proximity in the nucleus of nonrepeated sequences ( 12, 13) . The long-standing assumption of random, constant, and gradual mutagenesis is refuted by observations that mutations occur more frequently when cells are maladapted to their environments, together with the discoveries of mechanisms by which mutations are targeted to specifi c genomic structures. These modifi cations of the modern synthesis assumptions could not have been predicted or found without exploration of molecular mechanisms.
Such a fusion of molecular mechanisms with evolution is needed because cancer and infectious disease are evolutionary problems that could be attacked at the molecular level. For example, when a pathogen defeats a host, it has won an evolutionary arms race with the host immune system; cancer, too, proceeds by the generation of phenotypic variation and selection of those cells that are most fi t to propagate (see the fi gure). Deep understanding of the mechanisms that generate variation at the molecular level invites the possibility of fundamentally new antipathogen and anticancer therapies: ones that block the ability to evolve, instead of (or in addition to) traditional chemotherapies that kill cells or stop them from growing. For example, inhibitors of Hsp90 are succeeding as antifungal therapy adjuncts that block the development of resistance to standard drugs ( 14) and are in trials as chemotherapeutic agents. Similarly, the heat shock response factor that regulates Hsp90 has emerged as a promising therapeutic target in cancer ( 15) . Conventional cancer chemotherapies target the products of tumor evolution (such as DNA replication, altered cell signaling that promotes rapid proliferation, or the release of factors by cancer cells that spur angiogenesis). "Anti-evolvability" therapies could potentially stem the torrent of generation of variation that creates all of the products of evolution, whether targetable directly by drugs or not, thereby blocking the processes of tumor or pathogen evolution (see the fi gure).
The evolutionary biologist Theodosius Dobzhansky famously noted that "nothing in biology makes sense except in the light of evolution," but perhaps, too, "nothing in evolution makes sense except in the light of biology." Although the latter might be an exaggeration, an important gap is being fi lled by molecular understanding of the genesis of variation that confers the ability to evolve.
"Anti-evolvability" therapies. Multiple molecular mechanisms including mutation, protein conformational change, and epigenetic gene silencing create phenotypic variation that, with selection for the fi ttest cells, drives cancer initiation, progression, and resistance. Whereas conventional antiproliferative therapies target the products of this somatic cell evolution, proposed new therapies that block the evolutionary processes by which phenotypic variation is generated may be effective.
